San Francisco, 05 December 2025: The Report Blood Filtration And Purification Market (2025 - 2030) Size, Share & Trends Analysis Report By Product (Filtration Kits & Reagents, Membranes, Filters & Consumables, Sample Preparation Systems), By Application, By End-use, By Region, And Segment Forecasts

The global blood filtration and purification market size is anticipated to reach USD 5.63 billion by 2030 and is projected to grow at a CAGR of 7.34% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key driving factors such as increasing prevalence of blood-borne diseases, growing geriatric population, rising awareness of blood purification therapies have fueled the market growth.

The blood filtration & purification industry in clinical diagnostics experienced a major surge during the COVID-19 pandemic, driven by the urgent need for effective treatment solutions for critically ill patients. Among the most vital tools during this period were advanced blood purification kits, which played a critical role in managing severe inflammatory responses, organ failure, and complications associated with the virus.

At the forefront of this innovation was OXIRIS, a multifunctional blood purification filter set—the only one available in the U.S. capable of performing Continuous Renal Replacement Therapy (CRRT) while simultaneously removing cytokines and inflammatory mediators from the blood. During the height of the pandemic, OXIRIS became a key therapeutic solution for managing critically ill COVID-19 patients who were experiencing cytokine storms, sepsis, and acute kidney injury. By efficiently removing inflammatory substances, the kit helped stabilize patients, reduce intensive care burden, and improve survival outcomes.

Thermo Scientific's GeneJET Whole Blood Genomic DNA Purification Mini Kit stands out for its rapid, spin-column-based silica membrane technology. This kit streamlines DNA extraction from whole blood, eliminating the need for hazardous phenol-chloroform extraction or time-consuming alcohol precipitation. With a standard protocol that takes under 20 minutes post-lysis, it delivers high molecular weight DNA (>30 kb), ready for downstream applications like PCR, Southern blotting, and enzymatic assays. The kit’s simplicity and reliability make it a preferred choice for laboratories looking to scale genomic diagnostics with speed and safety.

SpiNXT Blood DNA Extraction Kit is another innovative solution, designed for use with whole blood, plasma, serum, lymphocytes, and buffy coat. Combining silica-binding chemistry with a mini spin-column format, it ensures high-yield, high-purity DNA isolations across a range of blood-derived sample types. With no need for organic solvents or complicated equipment, the SpiNXT kit enables fast processing and compatibility with a wide array of clinical genetic assays.

Meanwhile, the sbeadex Blood DNA Purification Kit brings magnetic bead-based technology into focus. Designed for sample volumes up to 200 µL, the kit supports high-throughput automation workflows and is fully compatible with popular platforms like Thermo Fisher's KingFisher™ system. Its water-based wash buffers help eliminate carryover of organic solvents and PCR inhibitors, ensuring clean DNA suitable for sensitive applications such as qPCR, NGS, Sanger sequencing, and genetic disorder screening.

Request sample report of Blood Filtration And Purification Market@ https://www.grandviewresearch.com/industry-analysis/blood-filtration-purification-market-report/request/rs1

The pandemic highlighted the critical role of blood purification kits in managing high-risk patients. As healthcare systems adapted to the challenges of COVID-19, these kits became indispensable tools not only for diagnostic support but also for therapeutic intervention. Their impact has extended beyond the pandemic, with continued use in managing sepsis, kidney injury, and other inflammation-driven conditions.

The COVID-19 crisis accelerated the adoption of blood filtration and purification kits such as OXIRIS, CytoSorb, AMBER, and Hemoclear, setting a new benchmark for integrated clinical diagnostics and critical care. These innovations remain central to modern ICU practice, ensuring that the lessons learned during the pandemic translate into stronger, more responsive healthcare systems going forward.

The rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) is a significant driver of the blood filtration and purification industry. Globally, approximately 9.1% of the population, or over 700 million individuals, are affected by CKD, with diabetes and hypertension being primary contributors to its progression to ESRD.

According to 2023 CDC, an estimated 35.5 million U.S. adults approximately 14% of the adult population-are affected by chronic kidney disease (CKD). This surge in CKD and ESRD cases leads to a heightened demand for dialysis services, including hemodialysis and peritoneal dialysis, which are essential for patients with kidney failure. Consequently, healthcare systems are expanding dialysis facilities and integrating advanced blood purification technologies to manage the increasing patient load. The rising incidence of these renal conditions underscores the critical need for effective blood filtration and purification solutions, thereby propelling market growth in this sector.

The blood filtration and purification industry within the field of clinical diagnostics is undergoing substantial growth, driven by the expanding global need for high-quality, analyte-rich samples in disease detection, monitoring, and personalized medicine. In modern diagnostics, the ability to efficiently process blood-separating plasma, serum, nucleic acids, or cells with minimal loss and contamination-is critical to the accuracy and reliability of downstream testing. Whether the goal is to detect viral RNA in an infectious disease panel, isolate circulating tumor DNA (ctDNA) in oncology, or analyze inflammatory cytokines in autoimmune diseases, robust and standardized blood purification processes are now a foundational component of the clinical diagnostic workflow. This shift has positioned blood filtration and purification tools as not just preparatory aids, but as integral diagnostic enablers.

One of the primary market drivers is the global rise in non-communicable diseases and complex conditions like cancer, sepsis, cardiovascular disorders, and autoimmune syndromes. These clinical areas increasingly rely on blood-based testing because of its minimally invasive nature, reproducibility, and rich information content. For instance, in oncology, liquid biopsies now allow clinicians to screen for tumor markers or mutations using just a few milliliters of blood, reducing the need for invasive tissue biopsies. This has led to a surge in demand for highly efficient purification systems that can isolate rare biomarkers like cfDNA, miRNA, or circulating tumor cells (CTCs) from whole blood with high specificity and sensitivity. Companies like Qiagen have responded to this need with products such as the QIAamp Circulating Nucleic Acid Kit, a widely adopted solution in both clinical and research labs that require reliable recovery of low-concentration nucleic acids.